Shares of Wockhardt Ltd. experienced a dramatic surge, climbing nearly 19% in early trading on Monday, following the announcement that its novel antibiotic, ZAYNICH, received approval from the U.S. Food and Drug Administration (FDA). This latest jump built on a 14.70% increase from the previous Friday, pushing the stock to a fresh record high of Rs 2,420 on the BSE and extending its one-month rally to 64%.
US FDA Approves ZAYNICH for Complicated UTIs
The FDA’s authorization for ZAYNICH marks a significant milestone for the Indian pharmaceutical major. ZAYNICH is an innovative intravenous antibiotic specifically developed for the treatment of adults suffering from complicated urinary tract infections (cUTI), including pyelonephritis, caused by susceptible Gram-negative pathogens. The drug is a multi-penicillin-binding protein targeting combination of the 4th generation cephalosporin cefepime and zidebactam, and had previously been granted Qualified Infectious Disease Product (QIDP) and Fast Track designations by the FDA.
Clinical Trials Demonstrate Strong Efficacy
The FDA approval was largely based on the robust results from ENHANCE-1, a Phase 3, randomized, double-blind, multicenter study. This trial evaluated ZAYNICH's efficacy, safety, and tolerability against meropenem in hospitalized adults with cUTI or acute pyelonephritis (AP). Wockhardt reported that ZAYNICH achieved an impressive composite clinical cure and microbiological response rate of 89%, significantly outperforming meropenem, which showed a rate of 68.4%. The treatment difference was a notable 20.6% (95% CI; 12.3, 29.5). The drug was generally well-tolerated across the 530 patients enrolled from various global sites, including the US, Europe, LATAM, China, and India.
"The approval is a significant realisation of our mission to provide patients with novel antibiotics that help to address one of the most urgent global health threats—antimicrobial resistance." — Habil F Khorakiwala, Founder and Chairman of Wockhardt Group
Before the comprehensive Phase 3 program, ZAYNICH underwent nine Phase 1 studies and a Phase 2 clinical study. The Phase 2 study, conducted across 15 leading tertiary care hospitals in India, demonstrated over 97% clinical efficacy against serious infections, including hospital-acquired bacterial pneumonia (HABP), ventilator-associated bacterial pneumonia (VABP), bloodstream infections (BSI), complicated intra-abdominal infections (cIAI), and cUTI. Furthermore, the Central Drugs Standard Control Organisation (CDSCO) in India had already authorized the import and marketing of ZAYNICH on May 28, preceding the US FDA's decision.
The FDA approval for ZAYNICH underscores Wockhardt's commitment to innovation in combating antimicrobial resistance, a critical global health challenge, and has been met with strong positive sentiment from the market.